Breathprinting (E-Nose) Technology to Measure Response to Treatment of Malignant Pleural Mesothelioma (MPM) Through MPM-Specific Volatile Organic Compounds Detected in Exhalates

Status: Recruiting
Location: See all (7) locations...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 85
Healthy Volunteers: f
View:

• Aged 30-85 years

• No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer)

• Recent diagnosis of MPM

• Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection

Locations
United States
New Jersey
Memorial Sloan Kettering Basking Ridge (Consent Only)
RECRUITING
Basking Ridge
Memorial Sloan Kettering Monmouth (Consent Only)
RECRUITING
Middletown
Memorial Sloan Kettering Bergen (Consent Only )
RECRUITING
Montvale
New York
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only)
RECRUITING
Commack
Memorial Sloan Kettering Westchester (Consent Only)
RECRUITING
Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITING
New York
Memorial Sloan Kettering Nassau (Consent Only)
RECRUITING
Uniondale
Contact Information
Primary
Gaetano Rocco, MD
roccog@mskcc.org
212-639-3478
Backup
David Jones, MD
212-639-6428
Time Frame
Start Date: 2023-09-08
Estimated Completion Date: 2026-09
Participants
Target number of participants: 20
Treatments
Experimental: E-Nose Technology
Patients undergo a breathprinting test (E-Nose) at baseline and at the first three standard of care follow-ups, as scheduled by their treating physician, that involve a CT of the Chest and/or PET/CT. The E-Nose testing will be administered by trained staff. Staff will use proper personal protective equipment during collections. Subjects will undergo E-Nose testing in a presurgical or interventional radiology suite. Subjects must consent to no smoking, no tooth brushing, and no food or drinks starting on midnight of the day of the E-Nose test. If fasting from midnight until the E-Nose test is not feasible, subjects may consent to fasting for 2 hours prior to each E-Nose test. Subjects opting to fast for 2 hours before each E-Nose test can only have still, non-carbonated water and non-aromatic foods or foods that do not develop aromatic compounds, such as low salt simple crackers, starting at midnight on the day of the E-Nose test until 2 hours before the collection.
Related Therapeutic Areas
Sponsors
Collaborators: UNIVERSITY CAMPUS BIO-MEDICO, ITALY
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials